Page 38 - Read Online

Page 14 of 14 Woods et al. J Cancer Metastasis Treat 2022;8:22 https://dx.doi.org/10.20517/2394-4722.2022.28

116. Strom T, Naghavi AO, Messina JL, et al. Improved local and regional control with radiotherapy for Merkel cell carcinoma of the
head and neck. Head Neck 2017;39:48-55. DOI PubMed
117. Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in Merkel cell carcinoma: a 15-year institutional experience and
statistical analysis of 721 reported cases. Br J Dermatol 2016;174:273-81. DOI PubMed
118. Lok B, Khan S, Mutter R, et al. Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer
2012;118:3937-44. DOI PubMed PMC
119. Tseng YD, Apisarnthanarax S, Liao JJ, Bhatia S, Nghiem PT, Parvathaneni U. Factors influencing radiation treatment
recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists. Expert Rev Anticancer Ther
2017;17:281-7. DOI PubMed
120. Jouary T, Leyral C, Dreno B, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma:
a multicentric prospective randomized study. Ann Oncol 2012;23:1074-80. DOI PubMed
121. Cook MM, Schaub SK, Goff PH, et al. Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and
Neck. Adv Radiat Oncol 2020;5:1248-54. DOI PubMed PMC
122. Bhatia S, Storer BE, Iyer JG, et al. Adjuvant radiation therapy and chemotherapy in merkel cell carcinoma: survival analyses of 6908
cases from the national cancer data base. J Natl Cancer Inst 2016;108:djw042. DOI PubMed
123. Rush Z, Fields RC, Lee N, Brownell I. Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert
Rev Dermatol 2011;6:395-404. DOI PubMed PMC
124. Płachta I, Kleibert M, Czarnecka AM, Spałek M, Szumera-Ciećkiewicz A, Rutkowski P. Current Diagnosis and Treatment Options
for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. Int J Mol Sci 2021;22:5077. DOI PubMed PMC
125. Płachta I, Kleibert M, Czarnecka AM, Spałek M, Szumera-Ciećkiewicz A, Rutkowski P. Current Diagnosis and Treatment Options
for Cutaneous Adnexal Neoplasms with Follicular Differentiation. Int J Mol Sci 2021;22:4759. DOI PubMed PMC
126. Dessinioti C, Plaka M, Soura E, et al. A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During
Treatment with Hedgehog Pathway Inhibitors. Oncologist 2019;24:e755-64. DOI PubMed PMC
127. D’Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma
(JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer 2021;9:e002646. DOI PubMed
PMC
128. Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the
CheckMate 358 Trial. J Clin Oncol 2020;38:2476-87. DOI PubMed PMC
129. Cowey CL, Robert NJ, Espirito JL, et al. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous
squamous cell carcinoma patients treated with systemic therapy. Cancer Med 2020;9:7381-7. DOI PubMed PMC
130. Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N
Engl J Med 2018;379:341-51. DOI PubMed
131. Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous
cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021;32:1276-85. DOI
PubMed
132. Maubec E, Boubaya M, Petrow P, et al. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With
Unresectable Cutaneous Squamous Cell Carcinomas. J Clin Oncol 2020;38:3051-61. DOI PubMed
133. Fujisawa Y, Yoshino K, Fujimura T, et al. Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for
Patients with Large Primary Tumor. Front Oncol 2018;8:46. DOI PubMed PMC